[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

May 2019 - July 1959

Decade

Year

Issue

April 2015, Vol 72, No. 4, Pages 379-481

In This Issue of JAMA Neurology

Highlights

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):379. doi:10.1001/jamaneurol.2014.2841
Viewpoint

How Critical Is the Blood-Brain Barrier to the Development of Neurotherapeutics?

Abstract Full Text
JAMA Neurol. 2015;72(4):381-382. doi:10.1001/jamaneurol.2014.3736

This Viewpoint reports that the blood-brain barrier is thought to restrict access of therapeutic agents that may otherwise be effective against central nervous system diseases. However, there is controversy in the neurotherapeutics community about the degree to which this hypothesis is true.

Measurement of Carotid Plaque Burden

Abstract Full Text
JAMA Neurol. 2015;72(4):383-384. doi:10.1001/jamaneurol.2014.3002

This viewpoint discusses the measurement of carotid plaque burden in determining cardiovascular risk factors.

Editorial

Circuits and Circuit Disorders: Approaches to Neuromodulation: Call for Papers and New Initiative With the American Neurological Association and the Annals of Neurology

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):385. doi:10.1001/jamaneurol.2015.0117

New Insights Into the Genetics of Autoimmune Myasthenia Gravis: An Evolving Story

Abstract Full Text
JAMA Neurol. 2015;72(4):386-387. doi:10.1001/jamaneurol.2014.4493

Treatment Decisions for Patients With Active Multiple Sclerosis

Abstract Full Text
JAMA Neurol. 2015;72(4):387-389. doi:10.1001/jamaneurol.2014.4494

Probing the Exome in Alzheimer Disease and Other Neurodegenerative Disorders

Abstract Full Text
JAMA Neurol. 2015;72(4):389-391. doi:10.1001/jamaneurol.2014.4495
Original Investigation

A Genome-Wide Association Study of Myasthenia Gravis

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):396-404. doi:10.1001/jamaneurol.2014.4103

This genome-wide association study provides insights into aberrant cellular mechanisms responsible for myasthenia gravis.

Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):405-413. doi:10.1001/jamaneurol.2014.4147

This retrospective data analysis finds that switching from injectable immunomodulators to fingolimod is associated with fewer relapses, more favorable disability outcomes, and greater treatment persistence compared with switching to another injectable preparation following on-treatment activity of multiple sclerosis.

A Multiancestral Genome-Wide Exome Array Study of Alzheimer Disease, Frontotemporal Dementia, and Progressive Supranuclear Palsy

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):414-422. doi:10.1001/jamaneurol.2014.4040

This genotyping study finds that low-frequency coding variants with intermediate effect size may account for a significant fraction of the genetic susceptibility to AD and frontotemporal dementia.

Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous Thrombolysis: A Retrospective Analysis of the Get With the Guidelines–Stroke Registry

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):423-431. doi:10.1001/jamaneurol.2014.4354

This retrospective analysis reports treatment complications and short-term outcomes in patients with mild ischemic stroke treated with intravenous thrombolysis.

Effects of Repetitive Transcranial Magnetic Stimulation on Motor Symptoms in Parkinson Disease: A Systematic Review and Meta-analysis

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):432-440. doi:10.1001/jamaneurol.2014.4380

The systematic review and meta-analysis suggests that repetitive transcranial magnetic stimulation improves motor symptoms for patients with Parkinson disease.

Deep Intronic GBE1 Mutation in Manifesting Heterozygous Patients With Adult Polyglucosan Body Disease

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):441-445. doi:10.1001/jamaneurol.2014.4496

This study identifies the deep-intronic mutation, which acts as a gene trap. This second-most common adult polyglucosan body disease mutation now explains another founder effect in all Ashkenazi-Jewish cases.

Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia: The Alzheimer’s Disease Cooperative Study Cognitive Function Instrument

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):446-454. doi:10.1001/jamaneurol.2014.3375

This longitudinal study found the Cognitive Function Instrument to be an informative potential outcome measure that provides insight into functional abilities at the earliest stages of Alzheimer disease.

Review

Nonmydriatic Ocular Fundus Photography in Neurologic Emergencies

Abstract Full Text
JAMA Neurol. 2015;72(4):455-459. doi:10.1001/jamaneurol.2014.4053

This review found that nonmydriatic ocular fundus photography has advantages over direct ophthalmoscopy that likely outweigh its associated costs.

Primary Familial Brain Calcification With Known Gene Mutations: A Systematic Review and Challenges of Phenotypic Characterization

Abstract Full Text
JAMA Neurol. 2015;72(4):460-467. doi:10.1001/jamaneurol.2014.3889

This systematic literature review provides a minimum data set to use for clinical and imaging data collection in primary familial brain calcification.

Clinical Implications of Basic Neuroscience Research

Modulation of GluN3A Expression in Huntington Disease: A New N-Methyl-d-Aspartate Receptor–Based Therapeutic Approach?

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):468-473. doi:10.1001/jamaneurol.2014.3953

This study concludes that information on the causative events of Huntington disease might help identify biomarkers that could be used to facilitate clinical trials.

Research Letter

Elevated Blood Mercury Levels in Idiopathic Axonal Neuropathy

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):474-475. doi:10.1001/jamaneurol.2015.1
Comment & Response

Stroke Care Within the Golden Hour

Abstract Full Text
JAMA Neurol. 2015;72(4):475. doi:10.1001/jamaneurol.2014.4568

Stroke Care Within the Golden Hour

Abstract Full Text
JAMA Neurol. 2015;72(4):475-476. doi:10.1001/jamaneurol.2014.4571

Stroke Care Within the Golden Hour—Reply

Abstract Full Text
JAMA Neurol. 2015;72(4):476-477. doi:10.1001/jamaneurol.2014.4574

Validation of the Association Between Neurologic Improvement With Decline in Blood Pressure and Recanalization in Stroke—Reply

Abstract Full Text
JAMA Neurol. 2015;72(4):477-478. doi:10.1001/jamaneurol.2014.4690

Validation of the Association Between Neurologic Improvement With Decline in Blood Pressure and Recanalization in Stroke

Abstract Full Text
JAMA Neurol. 2015;72(4):477. doi:10.1001/jamaneurol.2014.4705

Apolipoprotein E and Neurocognitive Function

Abstract Full Text
JAMA Neurol. 2015;72(4):478. doi:10.1001/jamaneurol.2014.4702

Apolipoprotein E and Neurocognitive Function—Reply

Abstract Full Text
JAMA Neurol. 2015;72(4):479. doi:10.1001/jamaneurol.2014.4699

Restless Genital Syndrome

Abstract Full Text
JAMA Neurol. 2015;72(4):479. doi:10.1001/jamaneurol.2015.20

Restless Genital Syndrome—Reply

Abstract Full Text
JAMA Neurol. 2015;72(4):479-480. doi:10.1001/jamaneurol.2015.23

Vaccination, Infection, and the Risk for Multiple Sclerosis

Abstract Full Text
JAMA Neurol. 2015;72(4):480. doi:10.1001/jamaneurol.2014.4708
Correction

Typographical Errors and Incomplete Affiliation

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):481. doi:10.1001/jamaneurol.2015.0111

Error in Reply Letter

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):481. doi:10.1001/jamaneurol.2015.0210

Error in Byline

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):481. doi:10.1001/jamaneurol.2015.0365
JAMA Neurology Masthead

JAMA Neurology

Abstract Full Text
free access
JAMA Neurol. 2015;72(4):380. doi:10.1001/jamaneurol.2014.2842
×